Eupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated by Analysts at Rodman & Renshaw

Rodman & Renshaw began coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in a research report released on Thursday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $9.00 price target on the stock.

Eupraxia Pharmaceuticals Price Performance

EPRX traded up $0.23 during trading on Thursday, hitting $3.13. 15,382 shares of the stock traded hands, compared to its average volume of 15,384. Eupraxia Pharmaceuticals has a twelve month low of $2.20 and a twelve month high of $5.58. The company has a market cap of $85.39 million and a price-to-earnings ratio of -4.08. The business has a 50 day moving average price of $2.66 and a 200 day moving average price of $2.68.

Institutional Trading of Eupraxia Pharmaceuticals

A hedge fund recently bought a new stake in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC acquired a new position in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 13,000 shares of the company’s stock, valued at approximately $34,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.